Tumor microenvironment pH (TME pH)

Tumor microenvironment pH refers to the characteristically acidic extracellular environment surrounding solid tumors. Normal tissue maintains an extracellular pH around 7.4, but tumor tissues exhibit markedly reduced pH values, typically ranging from 6.7 to 7.1, with some regions dropping as low as 5.5 to 6.0[1][3][4]. This acidification results from multiple factors including insufficient blood perfusion, hypoxia, and the Warburg effect—the preference of cancer cells for glycolytic metabolism even in the presence of oxygen[1][2][4]. The acidic tumor microenvironment develops through several interconnected mechanisms. Cancer cells exhibit increased glycolysis, producing excessive lactate and hydrogen ions[2][4]. To maintain a neutral to slightly alkaline intracellular pH (7.1-7.7), which is crucial for proliferation and survival, cancer cells export these acidic byproducts through various transporters including monocarboxylate transporters (MCT1, MCT4), sodium-hydrogen exchanger 1 (NHE1), and carbonic anhydrase IX (CAIX)[1][2]. This active acid extrusion acidifies the extracellular space while preserving an alkaline intracellular environment—a reversed pH gradient compared to normal cells[1][3]. The acidic tumor pH has profound effects on cancer progression. It promotes migration, invasion, and metastasis by increasing the activity of matrix metalloproteinases that degrade extracellular matrix components[1]. Acidosis creates an immunosuppressive environment by inhibiting the activation and proliferation of cytotoxic T cells, natural killer cells, and M1 macrophages while promoting regulatory T cells and M2 macrophages[2]. Additionally, the acidic environment contributes to both chemotherapy and radiotherapy resistance through multiple mechanisms, including altered drug uptake, inhibition of apoptosis, and reduced oxygen availability for radiation-induced DNA damage[1]. Tumor microenvironment pH has emerged as a therapeutic target with several approaches under investigation. These include inhibitors of acid-base regulators, buffering strategies to neutralize acidity, and modulation of pH-sensing G protein-coupled receptors (GPR4, GPR65, GPR68, GPR132) that mediate cellular responses to acidosis[4]. Understanding and targeting tumor pH represents a promising strategy for cancer therapy, as normalizing the tumor microenvironment could enhance immune function, improve drug delivery, and reduce metastatic potential.

Other names

Tumor pHTumor acidityTumor acidosisExtracellular pH in tumorsAcidic tumor microenvironmentTME acidosis

Therapeutic strategies targeting tumor pH work through: Inhibition of acid-base regulators (NHE1, MCT1, MCT4, carbonic anhydrase IX); Neutralization of extracellular acidity; Disruption of pH gradient between intracellular and extracellular spaces; Modulation of pH-sensing G protein-coupled receptors (GPR4, GPR65, GPR68, GPR132)